ASX-listed New Zealand company Volpara Health Technologies has been chosen to provide its VolparaDensity software to a research project being run by the NHS's breast screening program (NHSBSP) in England.
The project is the second stage of the Predicting Risk of Cancer at Screening (PROCAS) study, which aims to improve breast cancer risk prediction for women attending routine breast screening.